Cellect Biotech/S (Apop) Rating Reiterated by HC Wainwright

Cellect Biotech/S (Apop) Rating Reiterated by HC Wainwright


"We continue to expect that this cushion should be sufficient to fund operations through 2019. The January 2018 financing included unregistered warrants with an exercise price of $12.00 per ADS, which could if exercised in full accrue an additional $3.2M to the company.



from Biotech News